SAGE
Closed
Sage Therapeutic
9.08
-0.04 (-0.44%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 9.12
Day's Range: 9.05 - 9.13
Send
sign up or login to leave a comment!
When Written:
41.43
Sage Therapeutics is a biopharmaceutical company that focuses on developing and commercializing novel medicines to treat central nervous system (CNS) disorders. The company's lead product candidate is Zulresso (brexanolone), which is a proprietary intravenous formulation of allopregnanolone being developed for the treatment of postpartum depression (PPD). Zulresso was approved by the U.S. Food and Drug Administration (FDA) in March 2019.
Sage Therapeutics is also developing SAGE-217, an oral, once-daily neuroactive steroid for the treatment of major depressive disorder (MDD), bipolar depression, and PPD. The company is also exploring the potential of its compounds in other CNS disorders, including Huntington's disease, essential tremor, and Parkinson's disease.
Sage Therapeutics was founded in 2010 and is headquartered in Cambridge, Massachusetts. The company has partnerships with several pharmaceutical companies, including Shionogi & Co., Ltd., Biogen, and Takeda Pharmaceutical Company Limited.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Sage Therapeutics is also developing SAGE-217, an oral, once-daily neuroactive steroid for the treatment of major depressive disorder (MDD), bipolar depression, and PPD. The company is also exploring the potential of its compounds in other CNS disorders, including Huntington's disease, essential tremor, and Parkinson's disease.
Sage Therapeutics was founded in 2010 and is headquartered in Cambridge, Massachusetts. The company has partnerships with several pharmaceutical companies, including Shionogi & Co., Ltd., Biogen, and Takeda Pharmaceutical Company Limited.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








